Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Assembly Biosciences (NQ: ASMB )

13.10 +0.18 (+1.39%)
Streaming Delayed Price Updated: 12:44 PM EDT, Apr 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Assembly Biosciences

< Previous 1 2 3 Next >
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Assembly Biosciences Presents New Data Highlighting Entry Inhibitor and Core Inhibitor Programs at EASL’s International Liver Congress™ 2023
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL International Liver Congress™ 2023
From Assembly Biosciences, Inc.
Via GlobeNewswire
Disappointing Data Forces Assembly Bio Stop Combo Trial For HBV Infection
Via Benzinga
Assembly Biosciences to Present During the 2023 Jefferies Healthcare Conference
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Announces Additional Promising Data from Phase 1a Clinical Trial Evaluating Highly Potent Next-Generation Core Inhibitor Candidate ABI-4334 and Provides Pipeline Update
From Assembly Biosciences, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Assembly Biosciences Provides Update on its Core Inhibitor Pipeline, Reports Fourth Quarter and Year End 2022 Financial Results and Recent Highlights
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Nominates First Herpesvirus Development Candidate ABI-5366, a Long-Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Shares Gain After Promising Early Cut Data From HBV Infection Programs
Assembly Biosciences Inc (NASDAQ: ASMB) announced interim efficacy, safety, and pharmacokinetic (PK) results from a Phase 1b study of ABI-H3733 (3733) and a Phase 1a study of ABI-4334 (4334). 
Via Benzinga
Assembly Biosciences Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 and ABI-4334
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Doses First Subject in Phase 1a Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of Investigational Next Generation Core Inhibitor ABI-4334
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights and Announces Upcoming Conference Participation
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV
From Assembly Biosciences, Inc.
Via GlobeNewswire
NVIDIA To $140? Plus This Analyst Cuts PT On Assembly Biosciences By 82%
  Truist Securities cut the price target on Assembly Biosciences, Inc. (NASDAQ: ASMB) from $11 to $2. Assembly Biosciences shares gained 2.6% to trade at $1.58 on Monday. 
Via Benzinga
Assembly Biosciences to Present Data in Four Poster Presentations at Upcoming AASLD The Liver Meeting®
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Bio Announces Retirement of John G. McHutchison, AO, MD as CEO and Appoints Current President and COO Jason A. Okazaki as Successor
Dr. McHutchison will continue to provide strategic counsel as board member and chairman of the Science & Technology Committee of the board 
From Assembly Biosciences, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2022
Upgrades 
Via Benzinga
Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
7 Penny Stocks That Could Triple in 2022
Penny stocks are affordable and some with credible business models in all likelihood have the potential to generate superior returns. 
Via InvestorPlace
Assembly Bio Commences Early-Stage Study of Drug to Treat Hepatitis B Viral Infection
Assembly Biosciences, Inc. (NASDAQ: ASMB) today announced Initiation of Phase 1b clinical study of its drug candidate ABI-H3733 for Chronic Hepatitis B Virus Infection 
Via Benzinga
The Daily Biotech Pulse: Third FDA Rejection For Verrica's Skin Disease Drug, Assembly Bio Terminates Hepatitis B Virus Pact, Consistency Data For Valneva's Chikungunya Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Week In Review: I-Mab Files For Hong Kong SPAC IPO To Acquire Life Science Company
I-Mab and one of its investors, VMS, have filed for a Hong Kong IPO of a SPAC that will raise funds to acquire a life science company. Also, RVAC Medicines completed a Series B funding that brings... 
Via Talk Markets
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers XTL Biopharmaceuticals (NASDAQ:XTLB 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers iSpecimen (NASDAQ:ISPC) shares in... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Voyager Therapeutics (NASDAQ:VYGR) shares increased by 46.15% to $3.61 during Wednesday's pre-market session. The company's market cap stands at $136.9... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2021
Upgrades For Bank of America Corp (NYSE: 
Via Benzinga
The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2) Abbott Laboratories (NYSE:... 
Via Benzinga
65 Biggest Movers From Yesterday
Gainers AgileThought, Inc. (NASDAQ: AGIL) shares surged 69.4% to settle at $23.53 on Thursday. AgileThought 13D Filings from Chairman, CEO Manuel Senderos Fernández and... 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.